Hospitals | May 18, 2026
Medanta delivers record FY26 performance as revenue surges & profit jumps with expansion
Medanta expanded its bed capacity by 20% during the year
Medanta expanded its bed capacity by 20% during the year
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Subscribe To Our Newsletter & Stay Updated
